---
schema_version: "secwatch.filing_event.v1"
accession: "0001517022-23-000023"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2023-08-01T23:59:59+00:00"
generated_at: "2026-06-12T17:57:29.769929+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Akebia extends COO Dahan and CLO Hadas separation dates to 2024

## Summary
- COO Michel Dahan termination extended to March 22, 2024 (could extend to Sept 22, 2024 under certain events).
- Chief Legal Officer Nicole Hadas termination extended to Oct 6, 2023 (could extend to March 22, 2024).
- Both changes are amendments to retention/separation agreements from Nov 2022 and May 2023.
- Extensions are part of the workforce reduction announced May 9, 2022.

## SEC filing metadata
- accession: 0001517022-23-000023
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2023-08-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000151702223000023/0001517022-23-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000151702223000023/akba-20230726.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001517022-23-000023
- JSON: https://secwatch.observer/filing/0001517022-23-000023.json
- Plain text: https://secwatch.observer/filing/0001517022-23-000023.txt

## Key facts
- Executive change
  Nicole R. Hadas departed as Senior Vice President, Chief Legal Officer and Corporate Secretary at Akebia Therapeutics, Inc..
  - Action: extended termination date to
  - Role: Senior Vice President, Chief Legal Officer and Corporate Secretary
  source text: On July 26, 2023, the Company and Ms. Hadas agreed to further extend the effective date of her termination to October 6, 2023, and, in the event of certain specified events, the effective date of her termination may extend to March 22, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517022/000151702223000023/0001517022-23-000023-index.htm
- Executive change
  Michel Dahan departed as Chief Operating Officer at Akebia Therapeutics, Inc..
  - Action: extended termination date to
  - Role: Chief Operating Officer
  source text: On July 26, 2023, the Company and Mr. Dahan agreed to further extend the effective date of his termination to March 22, 2024, and, in the event of certain specified events, the effective date of his termination may extend to September 22, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517022/000151702223000023/0001517022-23-000023-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.